相关实验视频

Updated: Sep 12, 2025

Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis

Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis

Published on: June 27, 2020

抑制RUNX2会破坏PAX3::FOXO1-RUNX2的前循环,并拆除融合阳性狂宫肌肉瘤中的致癌基因程序

Elizabeth A Mendes^1,2, Aanandi Munshi¹, Archana Singh^3,4

¹Division of Pediatric Hematology-Oncology, Department of Pediatrics, Duke University School of Medicine, Durham, NC, USA.

bioRxiv : the preprint server for biology

|August 8, 2025

概括

RUNX2是融合阳性狂宫肌肉瘤 (FP-RMS) 的可用药物标. 抑制RUNX2抑制瘤生长并诱导细胞死亡,为这种侵袭性儿科癌症提供了一种新的治疗策略.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
儿科癌症研究儿童癌症研究

背景情况:

融合阳性狂宫肌肉瘤 (FP-RMS) 是一种具有攻击性的儿科癌症,其生存率很低,特别是在转移性疾病中.
PAX3::FOXO1融合基因驱动FP-RMS,但目前还不是一个可向的治疗蛋白质.
在FP-RMS中,急需新的治疗点.

研究的目的:

为了确定聚变阳性狂宫肌肉瘤中可用药物的标.
研究RUNX2作为FP-RMS中潜在的治疗点的作用.

主要方法:

在RMS患者的瘤和FP-RMS细胞系 (Rh30,Rh4) 上进行mRNA测序.
使用RNAi和小分子CADD522进行了体外功能丧失研究,以抑制RUNX2.2.
在异种移植模型中使用条件和药理抑制RUNX2进行了体内研究.

主要成果:

在FP-RMS中,RUNX2被确定为最高可药物依赖性.
抑制RUNX2抑制FP-RMS细胞生长,诱导肌体分化和亡,并模仿PAX3::FOXO1抑制.
在体内,RUNX2抑制显著降低了瘤生长.
在PAX3::FOXO1和RUNX2之间阐明了一个前循环,其中PAX3::FOXO1调节RUNX2,而RUNX2支持PAX3::FOXO1表达.

结论:

RUNX2是融合阳性狂宫肌肉瘤的关键治疗标.
准RUNX2为治疗这种侵袭性儿科癌症提供了一个有前途的新策略.
了解PAX3::FOXO1-RUNX2调节循环,可以提供有关FP-RMS病原性的机制性见解.

关键词:

在CADD52222中使用.在PAX3::FOXO1中,在RMS中使用RMS.在RUNX2中使用RUNX2.拉布多米索尔科马 (Rhabdomyosarcoma) 是一种癌症.

更多相关视频

Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells

Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells

Published on: September 1, 2019

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Published on: September 13, 2019

相关概念视频

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Induced Pluripotent Stem Cells

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...